Active Stocks
Thu Apr 18 2024 09:55:15
  1. Tata Steel share price
  2. 160.85 0.50%
  1. Power Grid Corporation Of India share price
  2. 279.75 1.97%
  1. Wipro share price
  2. 451.45 0.64%
  1. ITC share price
  2. 424.25 -0.40%
  1. Infosys share price
  2. 1,426.85 0.86%
Business News/ Markets / Ipo/  Windlas Biotech IPO to open on 4 Aug, close 6 Aug
BackBack

Windlas Biotech IPO to open on 4 Aug, close 6 Aug

The IPO consists of a fresh issue of ₹165 crore and an offer for sale of up to 5.14 million shares by its current promoters and shareholders

The offer for sale comprises 1.14 million shares by Vimla Windlass and 4.01 million shares by Tano India Pvt Equity Fund II. Photo: iStock (iStock)Premium
The offer for sale comprises 1.14 million shares by Vimla Windlass and 4.01 million shares by Tano India Pvt Equity Fund II. Photo: iStock (iStock)

Mumbai: Windlas Biotech Ltd's initial public offering will open on 4 August and close on 6 August.

The IPO consists of a fresh issue of 165 crore and an offer for sale of up to 5.14 million shares by its current promoters and shareholders.

Th offer for sale comprises 1.14 million shares by Vimla Windlass and 4.01 million shares by Tano India Pvt Equity Fund II. Currently, Vimla Windlass holds 7.8% stake while Tano India Pvt Ltd holds 22% stake in the company.

SBI Capital Markets, DAM Capital Advisors and IIFL Securities Ltd are the book running lead managers to the issue.

The proceeds from the issue worth 50 crore will be used to purchase equipment that is required for capacity expansion of its existing facility at Dehradun Plant IV and addition of injectables dosage capability at its existing facility.

The company will use 47.56 crore for funding incremental working capital requirements and 20 crore for repayment of certain debt. As of March 2021, its total outstanding borrowings amounted to 32.16 crore.

For the fiscal year 2021, revenue from operations stood at 427.60 crore versus 328.85 crore a year ago. Net profit for the period stood at 15.57 crore against 16.21 crore in the same period last year.

The firm is among the top five players in the domestic pharmaceutical formulations contract development and manufacturing organization (CDMO) industry in India in terms of revenue. It has also two strategic operations -- domestic trade generics and over-the-counter (OTC) brands, and exports.

The company currently owns and operates four manufacturing facilities located at Dehradun in Uttarakhand. As of December 2020, its manufacturing facilities had an aggregate installed operating capacity of 7,063.83 million tablets/ capsules, 54.46 million pouches/sachet and 61.08 million liquid bottles

Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
More Less
Published: 26 Jul 2021, 01:03 PM IST
Next Story footLogo
Recommended For You
GENIE RECOMMENDS

Get the best recommendations on Stocks, Mutual Funds and more based on your Risk profile!

Let’s get started
Switch to the Mint app for fast and personalized news - Get App